Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG

PURPOSE: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive malignant central nervous system (CNS) tumors (stratum 1) and post-radiation pre-progression diffuse intrinsic pontine glioma (DIPG) (stratum 2). PATIENTS AND METHODS: This prospective phase 1 study conducted by the Pediatric Brain Tumor Consortium evaluated sotigalimab using a 3+3 design for dose escalation. Immune pharmacodynamics were assessed with RNA transcript analysis, T cell receptor sequencing, and cytokine profiling. RESULTS: 31 eligible patients were enrolled (stratum 1: 20, stratum 2: 11). The stratum 1 recommended phase 2 dose was 0.6 mg/kg every 3 weeks; the stratum 2 maximum tolerated dose was 0.3 mg/kg every 3 weeks. Five patients had dose-limiting toxicities. No patients had an objective response. For stratum 1, 6-month and 12-month progression-free survivals (PFS) were 13.3% (standard error [SE], 8.1%) and 6.7% (SE, 6.2%), respectively; for stratum 2, 6-month PFS and overall survival were 31.2% (SE, 14.8%) and 44.4% (SE, 16.6%), respectively. At all dose levels, the maximum serum concentration was reached at the end of infusion; no drug accumulation was detected. More than 40% of patients developed anti-drug antibodies. Signaling pathways associated with activated antigen presenting cells and T cells were enriched in patients with higher PFS, while increased loss of heterozygosity was noted in patients with lower PFS. CONCLUSIONS: Sotigalimab was well-tolerated in pediatric patients with recurrent or progressive CNS tumors and post-radiation pre-progression DIPG.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-06-30
DOI
https://doi.org/10.1158/1078-0432.ccr-26-0655
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG

Tina Young Poussaint, Jason Fangusaro, Tobey J. MacDonald, Markos L. Leggas et al.
Clinical Cancer Research
Glioma Diagnosis and Treatment
article

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG

Tina Young Poussaint, Jason Fangusaro, Tobey J. MacDonald, Markos L. Leggas, Tyler Alban, Danny N. Khalil, Mehmet Koçak, Phillip Wong, Raghvendra M. Srivastava, Holly Lindsay, Nathan Robison, Anna Vinitsky, Eugene Hwang, Alicia Lenzen, Paul G. Pavicic, Catherine A. Billups, Arzu Onar‐Thomas, Ira J. Dunkel, C. Marcela Díaz‐Montero, Timothy A. Chan, Ian F. Pollack, Prerana Bangalore Parthasarathy, Vladimir Makarov, Benjamin Kovacic, Patricia Baxter, Ivan Juric
article en

Abstract

PURPOSE: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive malignant central nervous system (CNS) tumors (stratum 1) and post-radiation pre-progression diffuse intrinsic pontine glioma (DIPG) (stratum 2). PATIENTS AND METHODS: This prospective phase 1 study conducted by the Pediatric Brain Tumor Consortium evaluated sotigalimab using a 3+3 design for dose escalation. Immune pharmacodynamics were assessed with RNA transcript analysis, T cell receptor sequencing, and cytokine profiling. RESULTS: 31 eligible patients were enrolled (stratum 1: 20, stratum 2: 11). The stratum 1 recommended phase 2 dose was 0.6 mg/kg every 3 weeks; the stratum 2 maximum tolerated dose was 0.3 mg/kg every 3 weeks. Five patients had dose-limiting toxicities. No patients had an objective response. For stratum 1, 6-month and 12-month progression-free survivals (PFS) were 13.3% (standard error [SE], 8.1%) and 6.7% (SE, 6.2%), respectively; for stratum 2, 6-month PFS and overall survival were 31.2% (SE, 14.8%) and 44.4% (SE, 16.6%), respectively. At all dose levels, the maximum serum concentration was reached at the end of infusion; no drug accumulation was detected. More than 40% of patients developed anti-drug antibodies. Signaling pathways associated with activated antigen presenting cells and T cells were enriched in patients with higher PFS, while increased loss of heterozygosity was noted in patients with lower PFS. CONCLUSIONS: Sotigalimab was well-tolerated in pediatric patients with recurrent or progressive CNS tumors and post-radiation pre-progression DIPG.

Clinical Cancer Research
Northwestern University (US), St. Jude Children's Research Hospital (US), Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), Children's National (US), Children's Hospital of Los Angeles (US), Emory University (US), University of Pittsburgh (US), Baylor College of Medicine (US), Istanbul Medipol University (TR), Boston Children's Museum (US), University of Colorado Anschutz Medical Campus (US)
Good health and well-being
Openalex Percentile: Top 8%
Glioma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.